Pharmaxis Submits US New Drug Application for Bronchitol
Release Date: 21/05/2012 12:00am
Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) seeking approval for Bronchitol® for the treatment of patients with cystic fibrosis in the United States. The FDA has previously granted Bronchitol Orphan Drug designation for the treatment of patients with cystic fibrosis.
Categories: News and Media